Watchful Waiting Cost-Effective for Pediatric Acute Otitis Media

Share this content:
Watchful Waiting Cost-Effective for Pediatric Acute Otitis Media
Watchful Waiting Cost-Effective for Pediatric Acute Otitis Media

TUESDAY, March 7, 2017 (HealthDay News) -- Implementation of the American Academy of Pediatrics guidelines of watchful waiting (WW) for acute otitis media (AOM) is cost-effective, according to research published online March 3 in Pediatrics.

Di Sun, M.D., from the Children's Hospital Los Angeles, and colleagues conducted a retrospective review of a random selection of 250 patients aged ≤18 years with AOM in the emergency department. Data on current practice of AOM management were incorporated into a decision-analytic cost-utility model to compare the cost-effectiveness of WW versus current practice.

The researchers found that 247 of the participants had AOM on physical examination. Of these, 93.5, 2.8, and 3.6 percent were prescribed antibiotics, underwent WW, and were sent home without an antibiotic prescription, respectively. On application of the American Academy of Pediatrics criteria to this population, 42.1 and 57.9 percent of patients met the conditions for immediate antibiotic prescription and qualified for WW, respectively. For every 1,000 patients with AOM in the modeled scenario, implementing WW resulted in 514 fewer immediate antibiotic prescriptions and 205 fewer antibiotic prescriptions used; a total of 14.3 disability-adjusted life-years were averted, with savings of $5,573. These findings were robust to sensitivity analysis.

"WW for AOM management is cost-effective," the authors write. "Implementing WW may improve outcomes and reduce health care expenditures."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »